Trials / Recruiting
RecruitingNCT05060783
Renal Cancer Detection With Liquid Biopsy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Zealand University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | GaGnostic | Plasma |
| DIAGNOSTIC_TEST | GaGnostic | Serum |
| DIAGNOSTIC_TEST | GaGnostic | Urine |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2025-07-01
- Completion
- 2027-07-01
- First posted
- 2021-09-29
- Last updated
- 2024-01-30
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05060783. Inclusion in this directory is not an endorsement.